Literature DB >> 8882406

Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies.

W Parker1, K Lundberg-Swanson, Z E Holzknecht, J Lateef, S A Washburn, S J Braedehoeft, J L Platt.   

Abstract

Just as anti-blood group A and anti-blood group B antibodies pose a strong humoral barrier to the transplantation of allogeneic organs or blood, xenoreactive natural antibodies directed against Gal alpha 1-3Gal pose a barrier to the transplantation of xenogeneic organs or blood. We tested the idea that, although "natural" iso-hemagglutinins and xenoreactive natural antibodies recognize distinct structures, they have a similar origin and function. Anti-A antibodies, anti-B antibodies, and xenoreactive natural antibodies were present in serum at similar concentrations and varied with age, gender, and the concentration of total IgM in serum in a similar manner. Anti-A antibodies, anti-B antibodies, and xenoreactive natural antibodies, unlike some elicited antibodies, had a high degree of thermal lability and bound more avidly at lower temperatures. The natural antibodies manifest remarkable homogeneity and high functional avidity for determinants on a cell surface but only a weak affinity for monovalent ligands. These findings suggest that anti-A antibodies, anti-B antibodies, and xenoreactive natural antibodies specific for Gal alpha 1-3Gal have a common origin and function and, given similar antigen density on target cells, provide similar humoral barriers to transplantation or transfusion and that these antibodies may be members of a common "family" of antibodies.

Mesh:

Substances:

Year:  1996        PMID: 8882406     DOI: 10.1016/0198-8859(95)00216-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  11 in total

1.  B-1 cells in the bone marrow are a significant source of natural IgM.

Authors:  Youn Soo Choi; Jacquelyn A Dieter; Kristina Rothaeusler; Zheng Luo; Nicole Baumgarth
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

Review 2.  Accommodation of grafts: implications for health and disease.

Authors:  Amy H Tang; Jeffrey L Platt
Journal:  Hum Immunol       Date:  2007-05-15       Impact factor: 2.850

Review 3.  Accommodation in organ transplantation.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Curr Opin Organ Transplant       Date:  2008-04       Impact factor: 2.640

Review 4.  Recent advances in the immunology of xenotransplantation.

Authors:  T Takahashi; S Saadi; J L Platt
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

5.  Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development.

Authors:  W Parker; P B Yu; Z E Holzknecht; K Lundberg; R H Buckley; J L Platt
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

6.  Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria.

Authors:  Karla J Posekany; H Keith Pittman; John F Bradfield; Carl E Haisch; Kathryn M Verbanac
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 7.  Infectious disease issues in xenotransplantation.

Authors:  R S Boneva; T M Folks; L E Chapman
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

8.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

9.  Profiling human serum antibodies with a carbohydrate antigen microarray.

Authors:  Oyindasola Oyelaran; Lisa M McShane; Lori Dodd; Jeffrey C Gildersleeve
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

10.  Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies.

Authors:  P Kralickova; J Kuhnova; O Soucek; P Vodarek; P Zak; M Simkovic; M Motyckova; L Smolej; E Mala; C Andrys; J Krejsek; V Thon
Journal:  J Immunol Res       Date:  2017-12-17       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.